Bristol-Myers Squibb Co. carried $42.9B in long-term debt against $10.2B in cash and equivalents at the end of fiscal year 2025. Long-term debt fell 10.0% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Bristol-Myers Squibb Co. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
BMY Debt & Cash by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $42.9B-10.0% | $47.6B+29.9% | $36.7B+4.6% | $35.1B-11.5% | $39.6B-18.1% | $48.3B+11.4% | $43.4B+668.5% | $5.6B-19.1% | $7.0B+22.0% | $5.7B-12.7% | $6.5B-9.6% | $7.2B-9.3% | $8.0B+21.5% | $6.6B+22.2% | $5.4B |
| Cash & Equivalents | $10.2B-1.3% | $10.3B-9.8% | $11.5B+25.7% | $9.1B-34.7% | $14.0B-3.9% | $14.5B+17.8% | $12.3B+78.6% | $6.9B+27.5% | $5.4B+27.9% | $4.2B+77.7% | $2.4B-57.2% | $5.6B+55.4% | $3.6B+116.5% | $1.7B-71.3% | $5.8B |
BMY Debt & Cash by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $41.8B-5.9% | $42.1B-5.3% | $42.2B-8.7% | $42.9B-10.0% | $44.5B-8.6% | $44.5B-9.0% | $46.2B-6.7% | $47.6B+29.9% | $48.7B+51.5% | $48.9B+41.0% | $49.5B+41.1% | $36.7B+4.6% |
| Cash & Equivalents | $9.6B-39.1% | $8.7B-30.8% | $9.6B-12.0% | $10.2B-1.3% | $15.7B+99.3% | $12.6B+100.2% | $10.9B+16.6% | $10.3B-9.8% | $7.9B+5.0% | $6.3B-24.8% | $9.3B+3.7% | $11.5B+25.7% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Bristol-Myers Squibb Co. financials
Frequently Asked Questions
Bristol-Myers Squibb Co. carried $42.9B in long-term debt against $10.2B in cash and equivalents at the end of fiscal year 2025.
Bristol-Myers Squibb Co. (BMY) long-term debt fell by 10.0% year over year, from $47.6B to $42.9B in fiscal year 2025.
Across the 15 fiscal years this page covers, Bristol-Myers Squibb Co. (BMY) long-term debt went from $5.4B in fiscal year 2011 to $42.9B in fiscal year 2025.
Bristol-Myers Squibb Co. (BMY) reported $41.8B in long-term debt in Q3 2026. This represents a decrease of 5.9% from the same quarter a year earlier.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Bristol-Myers Squibb Co. (BMY) reported on that line in every period on record.